Marcelo Cruz, VP of business Development and Marketing at Tjoapack, explores the secondary innovations poised to revolutionise the patient centricity of PFSs over the next decade.
Charles Virden, founder and CEO of VitalTE, and Lisa Stehno-Bittel, president and founder of Likarda, discuss a new approach to HRT delivery that would allow self-administration through infrequent injection.
The biologics market is expanding rapidly – with a compound annual growth rate of 15% predicted until 2027. But this new generation of drugs comes with unique challenges that require an innovative approach underpinned by extensive experience.
Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies secured a contract valued at up to $129 million to supply DuoDote, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS).
Vetter, a globally operating Contract Development and Manufacturing Organisation (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS syringe closure system.
Kindeva Drug Delivery and Emervax have announced an exclusive partnership to co-develop a solution for the administration of vaccines targeting a variety of emerging viruses.
Kindeva Drug Delivery and Emervax has announced an exclusive partnership to co-develop a solution for the administration of vaccines targeting a variety of emerging viruses.
Molex, a parent to Phillips Medisize, announced that it has completed, through an affiliate, the previously announced acquisition of Vectura Group from Vectura Fertin Pharma, a subsidiary of Philip Morris International.
Owen Mumford has announced that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute drug delivery device UniSafe has achieved rapid early growth in combination product sales in Japan.
Gerresheimer announces that the US Food and Drug Administration (FDA) granted SQ Innovation Tentative Approval for Lasix ONYU for the home treatment of fluid overload in congestive heart failure.
Neuraxpharm Group (Neuraxpharm) and Pharmathen have announced a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.
Portescap’s business development manager for medical applications, Dave Beckstoffer, explains how drive systems for wearable and automatic drug delivery devices are central to the patient outcome.
